Bansisons Tea Industries Ltd

Novyra Pharmachem Limited – Trading Window Closure from Oct 1, 2026 until further notice, 48 hours after the declaration of its Unaudited Financial Results for the Quarter ended September 30, 2026

Name change and strategic focus

• Name change approved to Novyra Pharmachem Limited; company expands into APIs, bulk drugs, CDMO services.
• Certificate of Incorporation for name change issued by ROC on 19 January 2026.
• New name to be updated with stock exchanges and depositories.
• Business focus includes manufacturing, processing, and global trading of APIs, bulk drugs, intermediates.

Financial results approved

• Board approved unaudited standalone Q1 30 June 2026 results.
• Audit Committee reviewed results prior to Board approval.
• Three reportable segments: Pharma, Real Estate, Tea Estate.
• Results prepared under Ind AS 34 interim reporting.

Name change and corporate identity

• Name changed to Novyra Pharmachem Limited from Bansisons Tea Industries Ltd.

Auditor reporting and regulatory notes

• Independent Auditor's Review Report conducted; no material misstatement observed.
• Results are unaudited and standalone; Ind AS 34 applied.

Board meeting details

• Board meeting held on 14 August 2026.

Meeting Details

• Board meeting on Friday, 14 August 2026, at the registered office of the company.

Key Agenda Items

• Unaudited financial results for the quarter ended 30 June 2026, with Limited Review Report.
• Any other business with the permission of the Chairman.

Dematerialisation processing status

• Securities received from depository participants for dematerialisation were processed.
• Mutilated dematerialisation certificates were cancelled after verification and depository names substituted in the register within 15 days.
• Securities dematerialised have been listed on the stock exchanges where the earlier issued securities are listed.

Independent Directors Meeting Outcome

• Reviewed performance of non-independent directors and entire board
• Assessed chairperson's performance with input from executive and non-executive directors
• Evaluated quality, quantity, and timeliness of management-board information flow

Meeting Details ️

• Independent Directors meeting scheduled for 20th March 2026 at the company's registered office.

Key Agenda Items

• Review performance of Non-Independent Directors and the Board as a whole.
• Review the Chairperson's performance.
• Assess quantity, quality, and timeliness of information flow.